G

APCKO gRNA1

APCKO gRNA2



Additional file 9: *LARGE2* expression in mouse adenoma, and human engineered adenoma organoid (ADO) pairs carrying different *APC* truncation mutations

A) In-situ hybridization on mouse ileum tissue from FFPE sections with a *Large2* specific probe (top and middle) or without probe (control, bottom). Scale bars indicate 100 µm.

B,C) Immunohistochemistry staining on FFPE sections of mouse heart muscle tissue, using IIh6 antibody as positive control (**B**) for α -DG staining and IgM as negative control (**C**). Scale bar indicates 50 µm.

D,E) In-situ hybridization of a *Large2* probe (**D**) and control probe (**E**) on mouse ileum from APCmin mice. Black arrowhead indicates specific staining at the crypt base; grey arrowhead indicates staining in Wnt-driven adenoma. Clear arrowheads show lack of staining in the control experiment.

F,G) Mutation detection assay on genomic DNA derived from additional human normal mucosa organoids (wt) or *APC* mutated adenoma organoids PDO3 (mut, ex7, MCR) (**F**) and sanger sequencing profile (**G**) of both *APC* mutated organoid lines (Top: ADO3-ex7, Bottom: ADO3-MCR). Shown are deletions and frameshifts indicative of CRISPR/Cas9-mediated mutations in *APC* in PDO3.

H) qRT-PCR analysis of the indicated genes in adenomas engineered by CRISPR/Cas9-mediated targeting of *APC* in normal mucosa (ADO3-MCR versus ADO3-ex7). Shown is the mean ± SD (n=3). * p < 0.01, *** p < 0.001, **** p < 0.0001